Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Bardet-Biedl syndrome in which the cause of the disease is a mutation in the WDPCP gene.
WDPCP function has not been fully characterized.
Bardet-Biedl syndrome 15 is associated with mutations in the WDPCP gene on chromosome 2.
Genetic testing for WDPCP is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Bardet-Biedl syndrome 15 has been reported in the published literature.
No clinical trials have been registered for Bardet-Biedl syndrome 15.
25 publications have been identified in PubMed for Bardet-Biedl syndrome 15. Research spans Epidemiology / Natural History (32%), Basic Science / Preclinical (28%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 8 | 32% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:56 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Bardet-Biedl syndrome 15
Laboratory research
7 |
28% |
Patient case studies | 4 | 16% |
Research summaries | 2 | 8% |
Clinical study results | 2 | 8% |
Other research | 1 | 4% |
Testing and diagnosis research | 1 | 4% |
Seyedtaghia MR (2026). [PMID: 40252141](https://pubmed.ncbi.nlm.nih.gov/40252141/). *Biochem Genet*. [Epidemiology / Natural History]
Varughese RS (2026). [PMID: 42044156](https://pubmed.ncbi.nlm.nih.gov/42044156/). *J Clin Endocrinol Metab*. [Clinical Trial Publication]
Thiriveedi D (2026). [PMID: 41766136](https://pubmed.ncbi.nlm.nih.gov/41766136/). *Clin Endocrinol (Oxf)*. [Epidemiology / Natural History]
Hühne T (2026). [PMID: 40903014](https://pubmed.ncbi.nlm.nih.gov/40903014/). *J Clin Endocrinol Metab*. [Epidemiology / Natural History]
Mahler EA (2026). [PMID: 41238926](https://pubmed.ncbi.nlm.nih.gov/41238926/). *Ophthalmologie*. [Clinical Trial Publication]
Jena D (2026). [PMID: 41641302](https://pubmed.ncbi.nlm.nih.gov/41641302/). *AACE Endocrinol Diabetes*. [Case Report / Case Series]
Keifer E (2026). [PMID: 41947757](https://pubmed.ncbi.nlm.nih.gov/41947757/). *Clin Neuropsychol*. [Epidemiology / Natural History]
Clément K (2025). [PMID: 40744503](https://pubmed.ncbi.nlm.nih.gov/40744503/). *Clin Obes*. [Other]
Rustad CF (2025). [PMID: 40262952](https://pubmed.ncbi.nlm.nih.gov/40262952/). *BMJ Open*. [Epidemiology / Natural History]
Bea-Mascato B (2025). [PMID: 41193622](https://pubmed.ncbi.nlm.nih.gov/41193622/). *Sci Rep*. [Basic Science / Preclinical]
AI-curated news mentioning Bardet-Biedl syndrome 15
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.